( is a publicly traded biopharmaceutical business engaged in the discovery and development of novel drug candidates for the treatment of cancer and neurological illnesses such as for example Alzheimer’s, epilepsy, depression and pain. The company’s lead drug candidates exhibit high, nonexclusive affinity for sigma receptors, which were extensively documented as potentially valuable drug targets and have demonstrated evidence for neuroprotective and anti-amnesic properties. The company is developing non-amyloid concentrated methods to disease modification in Alzheimer’s disease. ANAVEX 1-41 and ANAVEX 2-73 modulate sigma receptors, a distinctive course of receptor molecules, to guard against oxidative tension and work through alternate mitochondrial pathways via ion channel signalling.Norman will discuss what elements are essential to create the most efficient health ecosystem, which he defines as the interplay of the environment, personal attributes and relationships, cultural influences, health and technology assets that impact individual wellness. Specifically, he’ll address: Why traditional health care models are not effectiveHow the emerging patient-centric health care model addresses weaknesses in today’s systemWhy behavior change is an essential element of a well organized health ecosystemThe components of effective behavior modification programsHow to create, sustain and progress a culture of wellness in the workplaceThe need for effective measuring equipment to evaluate impactWhy health is a very important investment for businesses THE POPULACE Health and Disease Administration Colloquium provides fresh insights about issues linked to chronic care administration, wellness and prevention, health promotion, consumerism and access to care.